We have made significant strides with our pipeline and Klarity™ Platform, thanks to the work of our internal team of intrepid scientists and our enabling and drug discovery collaborations. We thrive on bringing together diverse perspectives from both inside and outside of our company.
As we continue to unlock the potential of innovative oral therapeutics for metabolic, neurological, and gastrointestinal diseases, we are particularly interested in industry or academic collaborations that further enable the understanding of gut cell targets and intersecting chemical matter in the following key therapeutic areas:
Kallyope has developed a powerful screening platform that uniquely enables the identification of new pathways that modify gut biology. We are excited to combine their scientific expertise with our world-leading G protein-coupled receptor platform to identify and validate novel targets for potential in treating gastrointestinal disease, a key focus for our company.